280773-16-2

Basic information

• Product Name: 2-nitro-N-(5-chloro-pyridin-2-yl)-5-methoxy-benzamide
• Synonyms: 2-nitro-N-(5-chloro-pyridin-2-yl)-5-methoxy-benzamide;N-(5-Chloro-2-pyridinyl)-5-Methoxy-2-nitrobenzaMide;N-(5-Chloropyridin-2-yl)-5-methoxy-2-nitrobenzamide
• CAS NO: 280773-16-2
• Molecular Formula: C₁₃H₁₀ClN₃O₄
• Molecular Weight: 308
• Mol File: 280773-16-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 433.598°C at 760 mmHg
• Flash Point: 216.033°C
• Appearance: /
• Density: 1.469
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.657
• Storage Temp.: 2-8°C
• PKA: 10.38±0.70(Predicted)
• CAS DataBase Reference: 2-nitro-N-(5-chloro-pyridin-2-yl)-5-methoxy-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-nitro-N-(5-chloro-pyridin-2-yl)-5-methoxy-benzamide(280773-16-2)
• EPA Substance Registry System: 2-nitro-N-(5-chloro-pyridin-2-yl)-5-methoxy-benzamide(280773-16-2)

Safety Data

• Hazardous Substances Data: 280773-16-2(Hazardous Substances Data)

Usage

General Description

2-Nitro-N-(5-chloro-pyridin-2-yl)-5-methoxy-benzamide is a chemical compound with the molecular formula C13H10ClN3O4. It is a nitrobenzamide derivative that contains a nitro group, a chlorine atom, a pyridine ring, and a methoxy group. 2-Nitro-N-(5-chloro-pyridin-2-yl)-5-methoxy-benzamide may have potential applications in pharmaceutical research and drug development due to its structural features and potential biological activities. However, further studies are needed to fully understand its properties and potential uses.

InChI:InChI=1/C13H10ClN3O4/c1-21-9-3-4-11(17(19)20)10(6-9)13(18)16-12-5-2-8(14)7-15-12/h2-7H,1H3,(H,15,16,18)

Upstream product

• 1882-69-5 5-methoxy-2-nitro-benzoic acid 
• 1072-98-6 5-chloro-2-pyridylamine 

Downstream Products

• 1639024-44-4 C₃₅H₄₅N₇O₆ 
• 1616693-65-2 C₂₅H₃₂ClN₅O₇ 
• 1616693-64-1 C₁₄H₁₀ClN₃O₆ 
• 1616693-63-0 C₁₅H₁₂ClN₃O₆ 
• 1616693-62-9 C₁₂H₈ClN₃O₄ 
• 1514962-30-1 5-(2-((6-amidohexyl)amino)-2-oxoethyoxy)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-N-(pyridine-2-yl)benzamide 
• 1147095-60-0 S-[4-(N-{2-[N-(5-chloro(2-pyridyl))carbamoyl]-4-methoxyphenyl}carbamoyl)phenyl]-S-methyl sulfoximide 
• 1147095-86-0 S-[4-(N-{2-[N-(5-chloro(2-pyridyl))carbamoyl]-4-methoxyphenyl}carbamoyl)phenyl]-S-methyl-N-(2-diethylamino-acetyl)sulfoximide 
• 1416698-97-9 2-(4-(N-(2-chloroacetyl)-S-methylsulfonimidoyl)benzamido)-N-(5-chloropyridin-2-yl)-5-methoxybenzamide 
• 330942-05-7 betrixaban 
• 280773-17-3 2-amino-N-(5-chloro-pyridin-2-yl)-5-methoxy-benzamide 

Relevant articles and documents

Improved preparation method of beta-caraban

The invention relates to the fields of organic chemistry and pharmacy, and particularly relates to an improved method for preparing betrixaban. Compared with the prior art, the method has the advantages that the defects of use of high-corrosion hydrogen chloride gas, heavy burden for 'three wastes' treatment, difficult refining and purification of products and the like can be overcome. The method is characterized in that a metal organic compound RMR' (M is selected from Mg and Zn, R is selected from Cl, Br, I, alkyl or aryl, and R' is selected from akly or aryl) is used for reacting with dimethylamine or salt thereof in an aprotic solvent; then the obtained reacting liquid reacts with the compound or salt thereof in a formula II to prepare betrixaban. The improved novel method has the advantages of use of easily available raw materials, mild reaction condition, convenience in operation, excellent product quality and low cost and is suitable for industrial large-scale production.

Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors

Factor Xa (fXa) is a crucial player in various thromboembolic disorders. Inhibition of fXa can provide safe and effective antithrombotic effects. In this study, a series of anthranilamide compounds were designed by utilizing structure-based design strategies. Optimization at P1 and P4 groups led to the discovery of compound 16g: a highly potent, selective fXa inhibitor with pronounced in vitro anticoagulant activity. Moreover, 16g also displayed excellent in vivo antithrombotic activity in the rat venous thrombosis (VT) and arteriovenous shunt (AV-SHUNT) models. The bleeding risk evaluation showed that 16g had a safer profile than that of betrixaban at 1 mg/kg and 5 mg/kg dose. Additionally, 16g also exhibited satisfactory PK profiles. Eventually, 16g was selected to investigate its effect on hypoxia-reoxygenation- induced H9C2 cell viability. MTT results showed that H9C2 cell viability can be remarkably alleviated by 16g.

Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: Application of weakly basic sulfoximine group as novel S4 binding element

A novel series of potent and efficacious factor Xa inhibitors which possesses sulfoximine moiety as novel S4 binding element in anthranilamide chemotype has been identified. Lead optimization at this novel P4 group led to many potent factor Xa inhibitors with excellent anticoagulant activity in human plasma. Selected compounds were dosed orally in rats and checked for their ex vivo prothrombin time prolonging activity, which resulted in identification of compound 5-chloro-N-(5-chloropyridin-2-yl)-2-(4-(N-(2-(diethylamino)acetyl)-S- methylsulfonimidoyl)benzamido)benzamide (18f). The detailed pharmacokinetic evaluation and subsequent metabolism study of 18f suggested the presence of an active metabolite. The compound 18f and its active metabolite 18b demonstrated excellent in vivo efficacy in both arterial and venous thrombosis model in rats and were found to be highly selective against related serine proteases. Based on this promising profile, compound 18f was selected for further evaluation.